Proteomics and Human Diseases

Dear Colleagues,

Proteins are vital biomolecules regulating most biological processes and molecular functions in the human body. The alteration in protein abundance, its post-translational modifications, cellular localization, and protein–protein interaction are closely related to the pathologies of human diseases. In the past two decades, proteomics has gradually developed into a cutting-edge technology in life science and medical research in the post-genomic era. In the field of medicine, proteomics assists in disease diagnosis, drug discovery, and personalized medicine. On the one hand, traditional functional proteomics strategies have been extensively used to characterize the abundance, localization, and post-translational modification of proteins in clinical samples and disease animal models, elucidate the molecular mechanisms of disease occurrence and development, and discover new disease treatment targets for innovative drug development. On the other hand, interactions between biomolecules can be screened through chemical proteomics and protein–protein interactomics to identify the direct protein targets of small-molecule compounds (including marketed drugs, endogenous metabolites, food-derived small molecules, and environmental pollutant small molecules), accelerating drug development.

In this Special Issue, we aim to showcase the most recent advances in proteomics-driven precision medicine, and it mainly includes, but is not limited to, the following topics of interest:

1. Development of new high-throughout and high-sensitivity methodologies and technologies for the quantitative proteomics of clinical samples, including tissues/organs, body fluids, and exosomes.
2. Identification of potential protein biomarkers for various human diseases including cancers, metabolic diseases, cardiovascular diseases, neurodegeneration diseases, etc.
3. Chemical proteomics to identify novel protein targets of small-molecule drugs, endogenous metabolites, and new environmental pollutants and to further elucidate biological function of their interaction.
4. Proteomics-based investigation of molecular mechanisms regulating the occurrence and development of human diseases.
5. Artificial Intelligence (AI)-assisted proteomics in therapeutic target identification and drug discovery.

This Special Issue focuses on the application of proteomics in precision medicine and human disease research and bridges the gap between proteomics and medical research in the current field, thus promoting the interdisciplinarity and communication among researchers in life sciences, proteomics, and clinical medicine, and accelerating proteomics to better serve human disease research.

Prof. Dr. Lei Fang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• proteomics
• clinical proteomics
• human diseases
• biomarker identification
• therapeutic target
• molecular mechanism
• cancers
• metabolic diseases
• cardiovascular diseases
• neurodegeneration diseases